HRT Financial
CVKD icon

HRT Financial’s Cadrenal Therapeutics CVKD Stock Holding History

HRT Financial’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$38K Buy
35,375
+6,320
+22% +$11.5K ﹤0.01% 4384
2026
Q2 		$97K Buy
+29,055
New +$138K ﹤0.01% 3625

Other funds holding CVKD

Courier Capital
Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return
Vectors Research Management
Vectors Research Management New York $362M AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

HRT Financial's CVKD Position: Q3 2026 in Review

HRT Financial increased its Cadrenal Therapeutics (CVKD) stake by 22% in Q3 2026, buying an estimated $11.5K and bringing the position to 35,375 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #4384.

HRT Financial first reported a position in CVKD in Q2 2026 and has held it in 2 quarters since. The position peaked at $97K in Q2 2026. 23 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

  • HRT Financial held 35,375 shares of Cadrenal Therapeutics worth $38K as of Q3 2026.
  • HRT Financial bought 6,320 Cadrenal Therapeutics shares in Q3 2026, an estimated $11.5K.
  • Cadrenal Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q3 2026, its #4384 holding.
  • HRT Financial first reported a position in Cadrenal Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • HRT Financial's Cadrenal Therapeutics position peaked at $97K in Q2 2026.
  • 23 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on HRT Financial's 13F filing for Q3 2026, filed 13 Nov 2026.